Compare L3Harris Technologies Inc (LHX) vs Oscar Health Inc (OSCR) Price & Performance

LHX trades at $277.71, down 1.52% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $2.72 exceeding the $2.53 expectation. Recent contract wins, including a U.S. Space Force satellite award and U.S. Army communication system orders, highlight ongoing defense sector strength. The stock's valuation includes a P/E of 30.46 and a net income margin of 7.71% for 2025.

The outlook for LHX is positive, supported by a robust $40.7 billion backlog and 75% analyst buy ratings with a $367.50 consensus price target, implying significant upside. Key risks include execution on major contracts, defense budget fluctuations, and competitive pressures. The recent dividend of $1.25 per share underscores financial health, but investors should monitor debt levels and geopolitical factors affecting defense spending.

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.